TriSalus Life Sciences: A Comprehensive Analysis of Commercial Success and Promising Drug Pipeline Prospects

TipRanksJul 2 18:46

Express News | TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

BreakingsJul 2 04:00

TriSalus Life Sciences Is Maintained at Buy by Canaccord Genuity

Dow JonesJun 27 21:54

Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Maintains $12 Price Target

Analyst UpgradesJun 27 21:44

CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $12

CCORF analyst William Plovanic maintains $TriSalus Life Sciences(TLSI.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 41.9%

Futu NewsJun 27 19:31 · Ratings

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

Business WireJun 27 05:45